만성 신장 질환의 위험에 대해 피험자를 스크리닝하기 위한 방법들 및 컴퓨터-구현 방법

    公开(公告)号:KR20200135444A

    公开(公告)日:2020-12-02

    申请号:KR20207030180

    申请日:2019-03-22

    Abstract: 본개시는만성신장질환 (CKD) 의위험에대해피험자를스크리닝하기위한방법에관한것이고, 그방법은: 피험자에대한복수의마커파라미터들을나타내는마커데이터를수신하는단계로서, 이러한복수의마커파라미터들은, 측정기간동안피험자에대해, 연령값, 크레아티닌의샘플레벨, 및알부민의샘플레벨을나타내는, 상기마커데이터를수신하는단계; 및, 복수의마커파라미터들로부터피험자에대한앓고있는 CKD 의위험을나타내는위험인자를결정하는단계를포함하고, 여기서, 상기결정하는단계는: 알부민의샘플레벨보다더 높게연령값에가중치를부여하는단계, 및, 알부민의샘플레벨보다더 높게크레아티닌의샘플레벨에가중치를부여하는단계를포함한다. 추가로, 만성신장질환 (CKD) 의위험에대해피험자를스크리닝하기위한컴퓨터-구현방법및 피험자를스크리닝하기위한방법이제공된다.

    ACETYLATION OF GP41 FRAGMENTS
    5.
    发明申请
    ACETYLATION OF GP41 FRAGMENTS 审中-公开
    GP41片段的乙酰化

    公开(公告)号:WO02103026A2

    公开(公告)日:2002-12-27

    申请号:PCT/EP0205782

    申请日:2002-05-27

    Abstract: A process for the production of an antifusogenic peptide of a length of about 10 to 50 amino acids in a prokaryotic host cell, characterized in that, under such conditions that inclusion bodies of said non-fusion antifusogenic peptide or said fusion peptide are formed, a) in said host cell there is expressed a nucleic acid encoding said antifusogenic peptide as a non-fusion peptide or encoding a fusion peptide of a length of about 14 to 70 amino acids consisting of said antifusogenic peptide N-terminally linked to a further peptide of a length of about 4 to 30 amino acids; b) said host cell is cultivated; c) said inclusion bodies are recovered and solubilized; d) in the case of said fusion peptide said antifusogenic peptide is cleaved off from said further peptide; and e) said antifusogenic peptide is isolated.

    Abstract translation: 一种在原核宿主细胞中生产长度约10至50个氨基酸的抗融合肽的方法,其特征在于,在形成所述非融合抗融合肽或所述融合肽的包涵体的条件下, )在所述宿主细胞中表达编码所述抗融合肽作为非融合肽或编码长度约为14至70个氨基酸的融合肽的核酸,所述融合肽由所述抗融合肽组成,所述融合肽与N-末端连接的另一个肽 长度约4至30个氨基酸; b)培养宿主细胞; c)所述包涵体被回收和溶解; d)在所述融合肽的情况下,所述抗融合肽从所述另外的肽切除; 和e)分离所述抗融合肽。

Patent Agency Ranking